Acute neurologic deterioration in a patient with asymptomatic Charcot-Marie-Tooth disease following three doses of Brentuximab-Vedotin

Leuk Lymphoma. 2024 Oct;65(10):1532-1534. doi: 10.1080/10428194.2024.2360520. Epub 2024 Jun 3.

Authors

Haridian de la Nuez Melián¹, Hugo Luzardo Henríquez¹, Alexia Suárez Cabrera¹, Ruth Stuckey¹, María Teresa Gómez-Casares^{1

2}

Affiliations

¹ Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain.
² Department of Medical Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain.

PMID: 38829355
DOI: 10.1080/10428194.2024.2360520

No abstract available

Keywords: CMTIA; Hodgkin lymphoma; brentuximab-Vedotin; chemotherapy; neuropathy.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Brentuximab Vedotin* / adverse effects
Brentuximab Vedotin* / therapeutic use
Charcot-Marie-Tooth Disease* / complications
Charcot-Marie-Tooth Disease* / diagnosis
Female
Humans
Male
Middle Aged

Substances

Brentuximab Vedotin
Antineoplastic Agents, Immunological